Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

clock • 4 min read

Investments in biotech have seen consistent, long-term appreciation, even before the explosive market rallies and the IPO boom of 2019-2021.

The biotech public market has dramatically outperformed the S&P500 index over the past two decades. Biotech returns have continued to increase for both public and private companies over the years. A growing majority of the approved drugs commercialized by large pharma companies are externally sourced through licensing and M&A deals with smaller biotech companies and start-ups. The rapid reactivity of the industry to address the Covid-19 pandemic has further enhanced investor confidence in this industry. As a result, historic amounts of capital have been deployed into the sector over the ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot